ライフサイエンスコーパス: Guillain-Barre syndrome

1 an increased short-term risk of epilepsy and Guillain-Barre syndrome.

2 rders, including microcephaly in infants and Guillain-Barre syndrome.

3 Cases of acute ZIKV are also associated with Guillain-Barre syndrome.

4 e care beds capacity to manage patients with Guillain-Barre syndrome.

5 5 accompanied by congenital microcephaly and Guillain-Barre syndrome.

6 e of the infection in the development of the Guillain-Barre syndrome.

7 with ZIKV infection before the onset of the Guillain-Barre syndrome.

8 an etiologic agent of fetal microcephaly and Guillain-Barre syndrome.

9 possible association between Zika virus and Guillain-Barre syndrome.

10 on has been linked to congenital defects and Guillain-Barre syndrome.

11 e patient because of multiorgan failure with Guillain-Barre syndrome.

12 ment disorder, 1 had encephalitis, and 1 had Guillain-Barre syndrome.

13 orldwide and is implicated in development of Guillain-Barre syndrome.

14 ccines used in the USA increased the risk of Guillain-Barre syndrome.

15 ng to stroke, and acute neuropathies such as Guillain-Barre syndrome.

16 eutralization of autoantibodies in the fatal Guillain-Barre syndrome.

17 orldwide and is implicated in development of Guillain-Barre syndrome.

18 possible association between vaccination and Guillain-Barre syndrome.

19 nts safety concerns about the development of Guillain-Barre syndrome.

20 as suspended because of an increased risk of Guillain-Barre syndrome.

21 ked to microcephaly, congenital disease, and Guillain-Barre syndrome.

22 ions, including irritable bowel syndrome and Guillain-Barre syndrome.

23 frequent antecedent of autoimmune neuropathy Guillain-Barre syndrome.

24 s as well as cases of the autoimmune disease Guillain-Barre syndrome.

25 nal neuropathy that closely resembled axonal Guillain-Barre syndrome.

26 nstem encephalitis or those with overlapping Guillain-Barre syndrome.

27 ical features in paralytic rabies and axonal Guillain-Barre syndrome.

28 in some cases of Miller Fisher syndrome and Guillain-Barre syndrome.

29 corticosteroids, in hastening recovery from Guillain-Barre syndrome.

30 es mapping their relationship to subtypes of Guillain-Barre syndrome.

31 its characteristic of multiple sclerosis and Guillain-Barre syndrome.

32 o a form of neuromuscular paralysis known as Guillain-Barre syndrome.

33 ecovery and impact the functional outcome of Guillain-Barre syndrome.

34 on in acute peripheral neuropathies, such as Guillain-Barre syndrome.

35 lipopolysaccharide has been associated with Guillain-Barre syndrome.

36 malformations (congenital Zika syndrome) and Guillain-Barre syndrome.

37 oimmune neuritis (EAN) is an animal model of Guillain-Barre syndrome.

38 nfectious sequelae of reactive arthritis and Guillain-Barre syndrome.

39 utoimmune neuritis (EAN), an animal model of Guillain-Barre syndrome.

40 e compatible with a role in the causation of Guillain-Barre syndrome.

41 onset of a syndrome diagnosed clinically as Guillain-Barre syndrome.

42 IVGG is a recognised treatment for Guillain-Barre syndrome.

43 disease, motor neuron disease, epilepsy and Guillain-Barre syndrome.

44 atments are needed to improve the outcome of Guillain-Barre syndrome.

45 an increased short-term risk of epilepsy and Guillain-Barre syndrome.

46 disease, motor neuron disease, epilepsy, and Guillain-Barre syndrome.

47 microcephaly, congenital malformations, and Guillain-Barre syndrome.

48 er from acute demyelinating diseases such as Guillain-Barre syndrome.

49 s human diseases, including microcephaly and Guillain-Barre syndrome.

50 as is linked to congenital birth defects and Guillain-Barre syndrome.

51 microcephaly, congenital malformations, and Guillain-Barre syndrome.

52 other severe neurological diseases, such as Guillain-Barre syndrome.

53 demyelinating polyneuropathy subtype of the Guillain-Barre syndrome.

54 ng evidence for Zika virus infection causing Guillain-Barre syndrome.

55 irus (ZIKV) infection has been linked to the Guillain-Barre syndrome.

56 rus and dengue virus infection in developing Guillain-Barre syndrome.

57 gical complications of the Miller-Fisher and Guillain-Barre syndromes.

58 mboembolic events, autoimmune disorders, and Guillain-Barre syndrome; 0.1 for anaphylaxis and death;

59 We interviewed 180 of 273 adults with the Guillain-Barre syndrome; 15 declined to participate, and

60 e Americas has unveiled microcephaly (1) and Guillain-Barre syndrome(2,3) as ZIKV-associated neurolog

61 kungunya infection; p<=0.0001), particularly Guillain-Barre syndrome (25 [61%] patients).

62 2 patients) or acute polyradiculoneuropathy (Guillain-Barre syndrome) (4/12).

63 Among the 68 patients with the Guillain-Barre syndrome, 50% were found to have bilatera

64 vritis with cranial nerve involvement (16%), Guillain-Barre syndrome (8%) and mixed motor and sensory

65 esses on the physician differential included Guillain-Barre syndrome (99 cases) and myasthenia gravis

66 evidence now exists that axonal subtypes of Guillain-Barre syndrome, acute motor axonal neuropathy (

67 rs found no evidence of an increased risk of Guillain-Barre syndrome after seasonal influenza vaccine

68 ring project identified an increased risk of Guillain-Barre syndrome after vaccination; however, some

69 Surges in congenital defects and Guillain-Barre syndrome alerted the world to the danger

70 immunoglobulin is an effective treatment for Guillain-Barre syndrome, although the mechanism of actio

71 uals was vaccinated in the UK, 21.5 cases of Guillain-Barre syndrome and 5.75 cases of sudden death w

72 The reporting rates of Guillain-Barre syndrome and anaphylaxis after TIV-HD rec

73 porting rates were calculated for reports of Guillain-Barre syndrome and anaphylaxis.

74 and unexpected clinical outcomes, including Guillain-Barre syndrome and birth defects, has brought a

75 s (ZIKV) to cause serious disease, including Guillain-Barre syndrome and birth defects, was not recog

76 matory CD4(+) T cells that is reminiscent of Guillain-Barre syndrome and chronic inflammatory demyeli

77 ral neuropathy that resembles human diseases Guillain-Barre syndrome and chronic inflammatory demyeli

78 i-tubulin autoantibodies are associated with Guillain-Barre syndrome and chronic inflammatory demyeli

79 In Guillain-Barre syndrome and CIDP intravenous immunoglobu

80 e Zika virus (ZIKV) has been associated with Guillain-Barre syndrome and fetal abnormalities, but the

81 ction of the link between ZIKV infection and Guillain-Barre syndrome and fetal neurological defects,

82 eports of a preceding respiratory illness in Guillain-Barre syndrome and has important implications f

83 view the occurrence and clinical features of Guillain-Barre syndrome and its variant, the Miller Fish

84 sequelae such as hemolytic uremic syndrome, Guillain-Barre syndrome and malnutrition.

85 treatment is beneficial in CIDP, but not in Guillain-Barre syndrome and may worsen MMNCB.

86 of recent outbreaks and concerning links to Guillain-Barre syndrome and microcephaly are incompletel

87 d complications of ZIKV infection, including Guillain-Barre syndrome and microcephaly, potential inte

88 with serious neurological anomalies such as Guillain-Barre syndrome and microcephaly.

89 ditions with a primary immune basis, such as Guillain-Barre syndrome and multiple sclerosis.

90 of therapeutic plasma exchange for managing Guillain-Barre syndrome and myasthenia gravis were publi

91 uch as acute disseminated encephalomyelitis, Guillain-Barre syndrome and neuromyelitis optica.

92 severe neuropathology in neonates as well as Guillain-Barre syndrome and other neurologic disorders i

93 ZIKV is associated Guillain-Barre syndrome and other neurological complicat

94 were evidences of two severe adverse events (Guillain-Barre Syndrome and paralysis) present in TIV.

95 casionally are similar to those described in Guillain-Barre syndrome and suggest a possible relations

96 t differ significantly between patients with Guillain-Barre syndrome and those in the two control gro

97 Two patients developed Guillain-Barre syndrome, and 3 of 4 pregnancies had adve

98 n a proportion of patients with motor axonal Guillain-Barre syndrome, and also provide an explanation

99 e (MFS) variant of the paralytic neuropathy, Guillain-Barre syndrome, and are believed to be the prin

100 (ZIKV) is an emerging virus associated with Guillain-Barre syndrome, and fetal microcephaly as well

101 patients with chronic motor neuropathies and Guillain-Barre syndrome, and GQ1b/ disialosyl antisera a

102 ction of smell and taste, muscle injury, the Guillain-Barre syndrome, and its variants.

103 ion that mimic botulism, such as stroke, the Guillain-Barre syndrome, and myasthenia gravis.

104 MENTARY ON THIS ARTICLE : In axonal forms of Guillain-Barre syndrome, anti-ganglioside antibodies bin

105 de, collaborative studies of the spectrum of Guillain-Barre syndrome are accruing data for clinical a

106 Diseases such as multiple sclerosis and Guillain-Barre syndrome are characterized not only by wi

107 Under the umbrella term of Guillain-Barre syndrome are several recognisable variant

108 europathy syndromes, some of which may mimic Guillain-Barre syndrome, as many will have a metabolic a

109 The relative risk of the Guillain-Barre syndrome associated with vaccination, adj

110 ratory failure is a frequent complication of Guillain-Barre syndrome, associated with high morbidity

111 ith a specific Penner serotype, and 14 of 16 Guillain-Barre syndrome-associated isolates tested in th

112 A total of 68 patients with the Guillain-Barre syndrome at six Colombian hospitals were

113 The modest risk of Guillain-Barre syndrome attributed to vaccination is con

114 of serotype O:19 strains from patients with Guillain-Barre syndrome but not in cores of nonneuropath

115 ture confirms the use of plasma exchange for Guillain-Barre syndrome but suggests that inadequate evi

116 Features initially suggested Guillain-Barre syndrome, but botulinum toxin was identif

117 e in access to nutrients; an outbreak of the Guillain-Barre syndrome caused by lack of chlorination c

118 er Fisher syndrome is a localized variant of Guillain-Barre syndrome, characterized by ophthalmoplegi

119 , nonlength-dependent neuropathies including Guillain-Barre syndrome, chronic inflammatory demyelinat

120 iffuse, nonlength-dependent neuropathies are Guillain-Barre syndrome, chronic inflammatory demyelinat

121 2 g/kg is effective as first-line therapy in Guillain-Barre syndrome, chronic inflammatory demyelinat

122 rts the use of intravenous immunoglobulin in Guillain-Barre syndrome, chronic inflammatory demyelinat

123 in the western hemisphere has been linked to Guillain-Barre syndrome, congenital microcephaly, and de

124 Guillain-Barre syndrome consists of at least four subtyp

125 Guillain-Barre syndrome developed following infliximab t

126 In addition, 15 patients in whom Guillain-Barre syndrome developed following TNFalpha ant

127 om the Miller Fisher syndrome variant of the Guillain-Barre syndrome developed while he was receiving

128 case-control study, cases were patients with Guillain-Barre syndrome diagnosed at the Centre Hospital

129 lmonella, Yersinia, and Shigella organisms), Guillain-Barre syndrome (due to Campylobacter organisms)

130 documented by RT-PCR among patients with the Guillain-Barre syndrome during the outbreak of ZIKV infe

131 stem represents a useful means of monitoring Guillain-Barre syndrome during the pandemic.

132 42 patients were diagnosed with Guillain-Barre syndrome during the study period.

133 peripheral neuropathy for the development of Guillain-Barre syndrome during Zika virus outbreaks.

134 n, and 3 patients had complete resolution of Guillain-Barre syndrome following therapy.

135 oisson-based analysis to compare the risk of Guillain-Barre syndrome following vaccination in each se

136 ination in the six weeks before the onset of Guillain-Barre syndrome for 19 patients.

137 ed risk interval analysis of chart-confirmed Guillain-Barre syndrome found an elevated but not statis

138 o increase in the risk of vaccine-associated Guillain-Barre syndrome from 1992-1993 to 1993-1994.

139 6 acute flaccid paralysis cases diagnosed as Guillain-Barre syndrome from 2000 through 2008 in childr

140 Guillain Barre syndrome (GBS) is the most common cause o

141 are strongly associated with axonal forms of Guillain Barre syndrome (GBS).

142 Surveillance for Guillain-Barre syndrome (GBS) after receipt of this vacc

143 Guillain-Barre syndrome (GBS) and chronic inflammatory d

144 Guillain-Barre syndrome (GBS) and Fisher syndrome (FS) a

145 tis (EAN) is considered the in vivo model of Guillain-Barre syndrome (GBS) and has been extensively s

146 lammatory demyelinating neuropathies such as Guillain-Barre syndrome (GBS) and its animal model, expe

147 and consequences of adult infection include Guillain-Barre syndrome (GBS) and meningoencephalitis.

148 thought to be involved in the triggering of Guillain-Barre syndrome (GBS) and Miller-Fisher syndrome

149 rus was a cause of the neurological disorder Guillain-Barre syndrome (GBS) and of microcephaly and ot

150 1 vaccine) and the prior association between Guillain-Barre syndrome (GBS) and the 1976 H1N1 influenz

151 We diagnosed 11 Guillain-Barre syndrome (GBS) cases among 71,904 COVID p

152 Americas has been associated with a surge in Guillain-Barre syndrome (GBS) cases.

153 ylobacter jejuni isolated from patients with Guillain-Barre syndrome (GBS) differ from isolates isola

154 case-control study where 24 cases developed Guillain-Barre syndrome (GBS) during the 2014 chikunguny

155 5 days of symptom onset on 369 patients with Guillain-Barre Syndrome (GBS) enrolled in a trial compar

156 An increased risk of Guillain-Barre syndrome (GBS) following administration o

157 Given the increased risk of Guillain-Barre Syndrome (GBS) found with the 1976 swine

158 Guillain-Barre syndrome (GBS) has been associated with s

159 Guillain-Barre syndrome (GBS) has been reported to be as

160 tween Campylobacter infection and subsequent Guillain-Barre syndrome (GBS) has been well documented.

161 e of neutralizing antibodies in Zika-induced Guillain-Barre syndrome (GBS) has not yet been investiga

162 national morbidity and mortality burden for Guillain-Barre syndrome (GBS) in the United States, a na

163 Guillain-Barre syndrome (GBS) is a postinfectious autoim

164 Guillain-Barre syndrome (GBS) is a postinfectious neurop

165 Guillain-Barre syndrome (GBS) is a rare, but potentially

166 Guillain-Barre syndrome (GBS) is an acute inflammatory d

167 Guillain-Barre syndrome (GBS) is an acute polyradiculone

168 Guillain-Barre syndrome (GBS) is an acute polyradiculopa

169 Guillain-Barre syndrome (GBS) is an acute postinfectious

170 Guillain-Barre syndrome (GBS) is an autoimmune disease c

171 Guillain-Barre syndrome (GBS) is an immune-mediated peri

172 te motor axonal neuropathy (AMAN) variant of Guillain-Barre syndrome (GBS) is associated with anti-GD

173 Guillain-Barre Syndrome (GBS) is believed to be caused b

174 asonal variation in incidence and subtype of Guillain-Barre syndrome (GBS) is contradictory, but has

175 Guillain-Barre syndrome (GBS) is the most common cause o

176 An unexplained increase in the risk of Guillain-Barre syndrome (GBS) occurred among recipients

177 are specific to O serotypes associated with Guillain-Barre syndrome (GBS) or whether they are freque

178 Clinically, Guillain-Barre syndrome (GBS) predominated among regions

179 a exchanges and intravenous immunoglobulins, Guillain-Barre syndrome (GBS) still carries non-negligib

180 tigenic targets of autoantibodies present in Guillain-Barre syndrome (GBS), a group of neuropathies w

181 oenteritis and often precedes development of Guillain-Barre syndrome (GBS), a life-threatening paraly

182 Guillain-Barre syndrome (GBS), a neurologic disease char

183 Guillain-Barre syndrome (GBS), a neurologic disease that

184 Guillain-Barre syndrome (GBS), an acute, immune-mediated

185 Guillain-Barre syndrome (GBS), an autoimmune disorder of

186 resent in patients with the motor variant of Guillain-Barre syndrome (GBS), and their pathological ro

187 been shown to be an antecedent infection in Guillain-Barre syndrome (GBS), but the clinical spectrum

188 Data on AFP, including Guillain-Barre syndrome (GBS), could be analyzed from a

189 The pathogenesis of Guillain-Barre syndrome (GBS), especially the classic in

190 V infection among patients hospitalized with Guillain-Barre syndrome (GBS), meningoencephalitis, or t

191 ested as essential for accurate diagnosis in Guillain-Barre syndrome (GBS).

192 ediate the postinfectious paralytic disease, Guillain-Barre syndrome (GBS).

193 sociated with acute immune neuropathy called Guillain-Barre syndrome (GBS).

194 are being explored in myasthenia gravis and Guillain-Barre syndrome (GBS).

195 h the development of the neurologic disorder Guillain-Barre syndrome (GBS).

196 ated in the pathogenesis of some variants of Guillain-Barre syndrome (GBS).

197 in the pathogenesis of Campylobacter-induced Guillain-Barre syndrome (GBS).

198 HS:19 is associated with the development of Guillain-Barre syndrome (GBS).

199 mmune attack is different in the subtypes of Guillain-Barre syndrome (GBS).

200 ysiologic features similar to those of human Guillain-Barre syndrome (GBS).

201 ns that include congenital abnormalities and Guillain-Barre syndrome (GBS).

202 cacy and anticipate outcome in patients with Guillain-Barre syndrome (GBS).

203 developmental disorders; (3) vaccine-induced Guillain-Barre syndrome (GBS); (4) vaccine-induced autoi

204 upport the hypothesis that C. jejuni induces Guillain-Barre syndrome (GBS); however, many questions a

205 d chronic autoimmune neuropathies, including Guillain-Barre syndromes (GBS) are often characterized b

206 risk of neurologic complications (including Guillain-Barre syndrome [GBS]) with ZIKV infection.

207 In 20 of these 42 patients (48%), the Guillain-Barre syndrome had a parainfectious onset.

208 41 (98%) patients with Guillain-Barre syndrome had anti-Zika virus IgM or IgG,

209 Patients with Guillain-Barre syndrome had electrophysiological finding

210 39 (93%) patients with Guillain-Barre syndrome had Zika virus IgM and 37 (88%)

211 ni infections with subsequent development of Guillain-Barre syndrome has increased concerns from a pa

212 ed by an immune attack on the axon ("axonal" Guillain-Barre syndrome) has been advanced primarily bas

213 de of action, and roles of complement in the Guillain-Barre syndrome have been controversial.

214 The concepts of Guillain-Barre syndrome have changed substantially over

215 About a quarter of patients with Guillain-Barre syndrome have had a recent Campylobacter

216 een described in eight patients to date, and Guillain-Barre syndrome in 19 patients.

217 IKV) and neurologic complications, including Guillain-Barre syndrome in adults and CNS abnormalities

218 quito-borne pathogen that has been linked to Guillain-Barre syndrome in adults and congenital microce

219 associated with congenital malformations and Guillain-Barre syndrome in adults have placed public hea

220 mans, including microcephaly in newborns and Guillain-Barre syndrome in adults.

221 mans, including microcephaly in newborns and Guillain-Barre syndrome in adults.

222 d other neurological defects in neonates and Guillain-Barre syndrome in adults.

223 use Congenital Zika Syndrome in neonates and Guillain-Barre syndrome in adults.

224 Zika virus infection could also cause Guillain-Barre syndrome in adults.

225 ital malformations, and its association with Guillain-Barre syndrome in adults.

226 s ability to cause microcephaly in utero and Guillain-Barre syndrome in adults.

227 to devastating congenital birth defects and Guillain-Barre syndrome in adults.

228 ngenital malformations in infants as well as Guillain-Barre syndrome in adults.

229 e occurrence of microcephaly in neonates and Guillain-Barre syndrome in adults.

230 Guillain-Barre syndrome in northern China occurs in two

231 Patients given a diagnosis of the Guillain-Barre syndrome in the 1992-1993 and 1993-1994 i

232 racterized the clinical features of cases of Guillain-Barre syndrome in the context of this ZIKV infe

233 nown as congenital Zika syndrome, as well as Guillain-Barre syndrome, in ZIKV-infected adults.

234 rican and the Caribbean be used to establish Guillain-Barre syndrome incidence rates.

235 re associated with a small increased risk of Guillain-Barre syndrome (incidence rate ratio 2.35, 95%

236 neuropathies include sensory variants of the Guillain-Barre syndrome, including Miller-Fisher syndrom

237 Guillain-Barre syndrome is a rare but serious health dis

238 The motor axonal variant of Guillain-Barre syndrome is associated with anti-GD1a imm

239 Guillain-Barre syndrome is now recognized as a heterogen

240 Guillain-Barre syndrome is often caused by Campylobacter

241 Guillain-Barre syndrome is the most common and most seve

242 Inflammatory demyelination of nerve in Guillain-Barre syndrome is triggered in most patients by

243 il and its association with microcephaly and Guillain-Barre syndrome led to accelerated vaccine devel

244 its likely association with microcephaly and Guillain-Barre syndrome make Zika an urgent public healt

245 bstantial mortality and morbidity, including Guillain-Barre syndrome, microcephaly and other fetal de

246 als, IVIg has been effective in treating the Guillain-Barre syndrome, multifocal motor neuropathy, ch

247 yelinating polyradiculoneuropathy (n=53) and Guillain-Barre syndrome (n=21).

248 res (n = 44), meningitis (n = 3), and other (Guillain-Barre Syndrome) (n = 1).

249 f human immunoglobulin in an animal model of Guillain-Barre syndrome, namely experimental autoimmune

250 ZIKV infection might also trigger Guillain-Barre syndrome, neuropathy, and myelitis.

251 In Guillain-Barre syndrome, newly described antibodies bind

252 Possible associations with microcephaly and Guillain-Barre syndrome observed in this outbreak have r

253 l neurological disorders (n = 8), seven with Guillain-Barre syndrome, one with brachial plexopathy, s

254 in a demyelinating neuropathy that may mimic Guillain-Barre syndrome or chronic inflammatory demyelin

255 an sural nerves and those from patients with Guillain-Barre syndrome or chronic inflammatory demyelin

256 invasion), neuromuscular complications (eg, Guillain-Barre syndrome or transient muscle dysfunctions

257 o pneumococcal infection), PCV13 and PPSV23 (Guillain-Barre syndrome), or PPSV23 (cellulitis).

258 ctic serious allergic reaction, anaphylaxis, Guillain-Barre syndrome, or invasive Hib disease.

259 the paralytic form, which closely resembles Guillain-Barre syndrome, or when a patient is comatose a

260 ected in a cohort of mechanically ventilated Guillain-Barre syndrome patients.

261 with dysglycemia in mechanically ventilated Guillain-Barre syndrome patients.

262 between dysglycemia and neurologic status in Guillain-Barre syndrome patients.

263 ding translated to about 1.6 excess cases of Guillain-Barre syndrome per million people vaccinated.

264 ts slightly more than one additional case of Guillain-Barre syndrome per million persons vaccinated a

265 os and attributable risks of excess cases of Guillain-Barre syndrome per million vaccinations.

266 The long-term sequelae (Guillain-Barre syndrome, reactive arthritis, and postinf

267 l might be an adjuvant therapy for improving Guillain-Barre syndrome recovery.

268 f glycosylated flagellin with development of Guillain-Barre syndrome remains speculative, but the pos

269 Guillain-Barre syndrome remains the most frequent neurol

270 virus (ZIKV), which causes microcephaly and Guillain-Barre syndrome, signals an urgency to identify

271 emic lupus erythematosus, myasthenia gravis, Guillain-Barre syndrome, skin blistering syndromes, and

272 Highly visible health conditions, such as Guillain-Barre syndrome, spontaneous abortion, or even d

273 In the Guillain-Barre syndrome subform acute motor axonal neuro

274 site-specific injury in acute AGAb-mediated Guillain-Barre syndrome subforms and their chronic count

275 te motor axonal neuropathy (AMAN), a form of Guillain-Barre syndrome that selectively affects motor n

276 re frequently than expected in patients with Guillain-Barre syndrome, this association is extremely r

277 eports of neurological sequelae ranging from Guillain Barre syndrome to microcephaly.

278 r of reports of influenza-vaccine-associated Guillain-Barre syndrome to the national Vaccine Adverse

279 ipid reactivity was studied in patients with Guillain-Barre syndrome using both ELISA and combinatori

280 mptoms of ZIKV infection and symptoms of the Guillain-Barre syndrome was 7 days (interquartile range,

281 ecember 1976 after an increased incidence of Guillain-Barre syndrome was attributed to the vaccine.

282 smitted, and an increase in the incidence of Guillain-Barre syndrome was reported in some countries d

283 During the same period, an increase in Guillain-Barre syndrome was reported, suggesting a possi

284 ocedures employed in people to help diagnose Guillain-Barre syndrome, we determined that nerve conduc

285 through March 2016, clusters of cases of the Guillain-Barre syndrome were observed during the outbrea

286 mbers of neurological complications, such as Guillain-Barre syndrome, were reported(13,14) together w

287 s mounting that Zika virus can contribute to Guillain-Barre syndrome which causes temporary paralysis

288 study did not control for infection prior to Guillain-Barre syndrome, which may have been a confounde

289 oneuropathy and in none of the patients with Guillain-Barre syndrome, which was confirmed by cell bin

290 nant women, their infants, and patients with Guillain-Barre syndrome who had traveled to areas with Z

291 Patients with Guillain-Barre syndrome who had Zika and chikungunya dua

292 In 18 of 42 patients (43%) with the Guillain-Barre syndrome who underwent laboratory testing

293 series method to investigate the relation of Guillain-Barre syndrome with influenza vaccine and influ

294 The severe, generalised manifestation of Guillain-Barre syndrome with respiratory failure affects

295 An association of Guillain-Barre syndrome with TNFalpha antagonist therapy

296 In contrast, the relative incidence of Guillain-Barre syndrome within 90 days of an influenzali

297 The relative incidence of Guillain-Barre syndrome within 90 days of vaccination wa

298 roup, 11 (0.5%) patients were diagnosed with Guillain-Barre syndrome within the first year after LNB

299 group 11 (0.5%) patients were diagnosed with Guillain-Barre syndrome within the first year after LNB

300 g microcephaly, congenital malformation, and Guillain-Barre syndrome, Zika virus (ZIKV) remains a per